- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01782235
Efficacy of Tocilizumab in Primary Sjögren's Syndrome. (ETAP)
A Randomized, Double-blind, Parallel, Placebo-controlled Trial to Evaluate the Efficacy of Tocilizumab for the Treatment of Primary Sjögren's Syndrome.
Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterized by lymphocytic infiltration leading to destruction of acinar and ductal cells and loss of glandular parenchyma. The main symptoms of pSS are dry eyes and dry mouth, diffuse pain, and fatigue. One third of patients develop systemic features, the most severe being lymphomas.
Serum IL-6 is increased in serum, saliva, and tears of patients with pSS. IL-6 plays a pivotal role in B-cell activation, a hallmark of the pathogenesis of pSS, and in T-cell differentiation. Tocilizumab, a recombinant humanised monoclonal antibody acts as an IL-6R antagonist. The aim of this randomised double blind placebo controlled trial iss to evaluate the efficacy of tocilizumab for the treatment of pSS.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Strasbourg, France, 67098
- Hôpitaux Universitaires de Strasbourg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria :
- Patient with primary Sjögren's syndrome according to the European - American consensus group criteria.
- ESSDAI score ≥ 5.
- In women in childbearing age, effective contraception during treatment and 3 months following treatment discontinuation.
Exclusion Criteria:
- Patient with previous history of therapy with tocilizumab.
- Prednisone treatment introduced two weeks before inclusion or a change in this drug dose within two weeks before inclusion.
- A prednisone dose ≥ 15 mg per day.
- Non-steroidal anti-inflammatory drugs, pilocarpine hydrochloride, cyclosporine, cimeviline if introduced within two weeks before inclusion.
- Therapy with methotrexate, Hydroxychloroquine, chloroquine, quinacrine, leflunomide, psychoactive drug if introduced within 8 weeks before inclusion or a dose change within 8 weeks before inclusion.
- Treatment with azathioprine or mycophenolate mofetil within 8 weeks before inclusion.
- Live and live attenuated vaccines given within 4 weeks before inclusion.
- Any biologic treatment within 6 month before inclusion.
- Treatment with cyclophosphamide, intravenous immunoglobulin therapy or plasmapharese therapy in the last 6 months before inclusion.
- Systemic auto-immune disease.
- Patient with previous history of diverticular perforations, complications of diverticulitis, peritonite or inflammatory bowel disease (such as Crohn's disease and Colitis ulcerative).
- Patient with history of severe infection within 4 weeks before inclusion.
- Patient with history of infection within 2 weeks before inclusion.
- Patient with chronic infection or infection returns (e.g. tuberculose, VHB, VHC…).
- Positive serology tests for HIV, HBV, HCV.
- Severe uncontrolled dyslipidemia.
- Hepatocellular insufficiency.
- Unstable cardiovascular disease.
- Severe or chronic kidney disease, severe or chronic lung disease, severe or chronic endocrine disorder, severe or chronic neurological disease ( not related to the SJP).
- Patient with history of solid organ transplantation or haematopoietic stem cell transplantation.
- Patient with history of lymphoma, neoplasia diagnosed 5 years before inclusion except squamous and basal cell cancers and carcinoma in situ of the uterine cervix.
- Severe complications of SJp at the inclusion: vasculitis with renal neurologic, digestive or cardiac involvement, interstitial lung disease, symptomatic cryoglobulinemia with severe neurologic involvement, renal function impairment, severe myositis, corticotherapy ≥ 1 mg/kg in the last 30 days before inclusion.
- Neutropenia < 1000*10^6 .
- Thrombocytopenia < 50 000/µl
- ALT or AST > 3 x ULN
- alcohol and drug addiction : withdrawal at least one year before inclusion
- A major surgical procedure in the 8 weeks before inclusion or a scheduled major surgery
- Pregnant woman, breast feeding woman
- Adults under supervision or guardianship
- Patient taking part in another clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tocilizumab arm
Tocilizumab arm will receive tocilizumab.
|
|
Placebo Comparator: Placebo arm
Placebo arm will receive placebo.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of the ESSDAI score equal to or greater than 3 points compared to enrollment.
Time Frame: 24 weeks
|
Improvement of the ESSDAI score equal to or greater than 3 points compared to enrollment, with no new domain with high activity of the ESSDAI compared to enrollment, and no clinical worsening according to the clinician (no worsening compared to enrollment greater than 1 point of the Systemic Activity 0-10 VAS according to the physician.
|
24 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jacques-Eric Gottenberg, Hôpitaux Universitaires de Strasbourg
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Eye Diseases
- Disease
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Stomatognathic Diseases
- Mouth Diseases
- Lacrimal Apparatus Diseases
- Arthritis, Rheumatoid
- Xerostomia
- Salivary Gland Diseases
- Dry Eye Syndromes
- Syndrome
- Sjogren's Syndrome
Other Study ID Numbers
- 5206
- 2012-002045-37 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Sjögren's Syndrome (pSS)
-
Assistance Publique - Hôpitaux de ParisRecruitingPrimary Sjögren's Syndrome (pSS)France
-
University Hospital, BrestRecruitingPrimary Sjögren's Syndrome (pSS)France
-
Samjin Pharmaceutical Co., Ltd.CompletedPrimary Sjögren's Syndrome (pSS)Korea, Republic of
-
argenxIqvia Pty LtdRecruitingPrimary Sjögren's SyndromeBelgium, Hungary, Poland
-
Peking University People's HospitalRecruitingPrimary Sjögren's SyndromeChina
-
Second Affiliated Hospital, School of Medicine,...RecruitingPrimary Sjögren's SyndromeChina
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
RemeGen Co., Ltd.CompletedA Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's SyndromePrimary Sjögren's SyndromeChina
-
National Institute of Allergy and Infectious Diseases...Biogen; Autoimmunity Centers of ExcellenceTerminatedPrimary Sjögren's SyndromeUnited States
-
Novartis PharmaceuticalsWithdrawnPrimary Sjögren's Syndrome
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States